FDA thumbs up for Allergan and Perrigo’s generic Mucinex products

11 September 2015

Ireland-incorporated Allergan (NYSE: ACT) has received US Food and Drug Administration approval for its Abbreviated New Drug Applications for three Mucinex equivalent products, a brand from Reckitt Benckiser.

Mucinex DM Regular Strength (guaifenesin 600mg and dextromethorphan 30mg);
Mucinex DM Maximum Strength (guaifenesin 1200mg and dextromethorphan 60mg); and
Mucinex Maximum Strength (guaifenesin 1200mg)

Allergan’s partner Perrigo (NYSE: PRGO) Perrigo, the subject of a now hostile bid from Mylan (Nasdaq: MYL; The Pharma Letter September 9), will begin shipments of the products to its retail and wholesale customers in the USA in time for the 2016 cough and cold season. These products will be packaged and marketed as store brands which will give consumers high quality, value alternatives to these Mucinex extended-release products.

This article is accessible to registered users, to continue reading please register for free. A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.

Try before you buy

Free

7 day trial access

Take a Free Trial

All the news that moves the needle in pharma and biotech
Exclusive features, podcasts, interviews, data analyses and commentary from our global network of life sciences reporters.
Receive The Pharma Letter daily news bulletin, free forever.

Become a subscriber

£820

Or £77 per month

Subscribe Now

Unfettered access to industry-leading news, commentary and analysis in pharma and biotech.
Updates from clinical trials, conferences, M&A, licensing, financing, regulation, patents & legal, executive appointments, commercial strategy and financial results.
Daily roundup of key events in pharma and biotech.
Monthly in-depth briefings on Boardroom appointments and M&A news.
Choose from a cost-effective annual package or a flexible monthly subscription

The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed

Chairman, Sanofi Aventis UK